Famciclovir for recurrent genital herpes

References

• Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes11(Suppl. 1), 2A–23A (2004).
   PubMedGoogle Scholar
• Apoola A, Radcliffe K. Antiviral treatment of genital herpes. Int. J. STD AIDS15, 429–433 (2004).
   PubMed Web of Science ®Google Scholar
• Nikkels AF, Pierard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am. J. Clin. Dermatol.3(7), 475–487 (2002).
   PubMedGoogle Scholar
• Nadelman CM, Newcomer VD. Herpes simplex virus infections. New treatment approaches make early diagnosis even more important. Postgrad. Med.107(3), 189–195, 199–200 (2000).
   PubMed Web of Science ®Google Scholar
• Brown ZA, Kern ER, Sprurance SL et al. Clinical and virologic course of herpes simples genitalis. West. J. Med.130(5), 414–421 (1979).
   PubMedGoogle Scholar
• Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin. Infect. Dis.26, 541–555 (1998).
   PubMed Web of Science ®Google Scholar
• Drob S, Loemer M, Lifschutz H. Genital herpes: the psychological consequences. Br. J. Med. Psychol.58(Pt 4), 307–315 (1985).
   PubMed Web of Science ®Google Scholar
• Barton SE, Ebel CE, Kirchner JT et al. The clinical management of recurrent genital herpes: current issues and future prospects. Herpes9(1), 15–20 (2002).
   PubMedGoogle Scholar
• ACOG Practice Bulletin. Clinical Management Guidelines for obstetrician–gynecologists; gynecologic herpes simplex virus infection. Obstet. Gynecol.104(5), 1111–1118 (2004).
   PubMedGoogle Scholar
• Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs66(18), 2397–2416 (2006).
   PubMed Web of Science ®Google Scholar
• Bacon TH. Famciclovir, from the bench to the patient: a comprehensive review of preclinical data. Int. J. Antimicrob. Agents7(2), 119–134 (1996).
   PubMed Web of Science ®Google Scholar
• Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir. Chem. Chemother.4(2), 67–84 (1993).
   Web of Science ®Google Scholar
• Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother.33(2), 223–229 (1989).
   PubMed Web of Science ®Google Scholar
• Thackray AM, Field HJ. Comparison effects of famciclovir and valacyclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother.40, 846–851 (1996).
   PubMed Web of Science ®Google Scholar
• Wutzler P, Ulbright A, Farber I. Antiviral efficacies of famciclovir, valacyclovir, and brivudin in disseminated herpes simplex type 1 infection in mice. Intervirology28(40), 15–21 (1997).
   Google Scholar
• Field HJ, Thackray AM. Early therapy with valacyclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency. Nucleos. Nucleot. Nucleic Acids19(1–2), 461–470 (2000).
   PubMed Web of Science ®Google Scholar
• Field HJ, Tewari D, Sutton D. Comparison of efficacies of famciclovir and valacyclovir against herpes simplex type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother.39, 1114–1119 (1995).
   PubMed Web of Science ®Google Scholar
• Thackray AM, Field HJ. Famciclovir and valaciclovir differ in the prevention of herpes simplex type 1 virus in mice: a quantitative study. Antimicrob. Agents Chemother.48, 1555–1562 (1998).
   Google Scholar
• Thackray AM, Field HJ. Differential effects of famciclovir and valacyclovir on the pathogensesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis.173, 291–299 (1996).
   PubMed Web of Science ®Google Scholar
• LeBlanc RA, Pesnicak L, Godleski M et al. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. J. Infect. Dis.180, 594–599 (1999).
   PubMed Web of Science ®Google Scholar
• Field HJ, Thackray AM. Early therapy with valacyclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency. Nucleos. Nucleot. Nucleic Acids19(1–2), 461–470 (2000).
   PubMed Web of Science ®Google Scholar
• Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol. Surg.25, 242–246 (1999).
   PubMed Web of Science ®Google Scholar
• Crumpacker C. The pharmacological profile of famciclovir. Semin. Dermatol.15(Suppl. 1), 14–26 (1996).
   PubMedGoogle Scholar
• Pue MA, Pratt SK, Fairless AJ et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother.33, 119–127 (1994).
   PubMed Web of Science ®Google Scholar
• Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir. Chem. Chemother.4, 47–55 (1993).
   Web of Science ®Google Scholar
• Boike SC, Pue M, Audet PR et al. Pharmakokinetics of famciclovir in subjects with chronic hepatic disease. J. Clin. Pharmacol.34, 1199–1207 (1994).
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY. Famciclovir for the management of genital herpes simplex in patients with inadequate response to acyclovir or valacyclovir. Clin. Drug Invest.25(12), 803–809 (2005).
   PubMed Web of Science ®Google Scholar
• Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first-episode genital herpes. Infect. Dis. Clin. Pract.6(Suppl. 1), S12–S16 (1997).
   Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Diaz-Mitoma F et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double blind multicenter trial. JAMA276, 44–49 (1996).
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Martel AY et al. Clinic-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized double-blind multicenter trial. Clin. Infect. Dis.41(8), 1097–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Aoki FY, Tyring S, Diaz-Mitoma F et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis.42, 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Chosidow O, Drouault Y, Leconte-Veyriac F et al. Famciclovir vs. acyclovir in immunocompetent patients with recurrent gential herpes infections: a parallel-group, randomized, double-blind clinical trial. Br. J. Dermatol.144, 818–824 (2001).
   PubMed Web of Science ®Google Scholar
• Wald A, Selke S, Warren T et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis.33(9), 529–533 (2006).
   PubMed Web of Science ®Google Scholar
• Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double dummy, placebo-controlled, parallel-group, single center trial. J. Infect. Dis.189(8), 1341–1347 (2004).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Diaz-Mitoma F, Shafran SD et al. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J. Cutan. Med. Surg.7(6), 449–454 (2003).
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Loveless MO, Levin MJ et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus in women: a multicenter, double-blind, placebo-controlled. Arch. Intern. Med.157, 343–349 (1997).
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Sibbald RG, Shafran SD et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA280, 887–892 (1998).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Berger T, Yen-Moore A et al. Single-day therapy for recurrent genital herpes. Am. J. Clin. Derm.7(4), 209–211 (2006).
   PubMed Web of Science ®Google Scholar
• Reitano M, Tyring S, Lang W et al. Valacyclovir for the suppression of recurrent genital herpes simplex infection: a large-scale dose range-finding study. J. Infect. Dis.178(3), 603–610 (1998).
   PubMed Web of Science ®Google Scholar
• Sprurance SL. Herpes simplex labialis. Clinical Management of Herpes Viruses. Sack SL, Strauss SE, Whitley RJ et al. (Eds). IOS Press, Amsterdam, The Netherlands, 3–24 (1995).
   Google Scholar
• Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med.350, 11–20 (2004).
   PubMed Web of Science ®Google Scholar